四川双马醋酸亮丙瑞林化学原料药上市申请获批

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Company Summary - Hubei Jianxiang Biopharmaceutical Co., Ltd. is now authorized to market Acetate Leuprolide, a GnRH agonist, which effectively suppresses the secretion of gonadotropins when administered continuously at therapeutic doses [1] - The approved indications for Acetate Leuprolide in China include treatment for endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]